Jason Jardine, Makoto Tsunozaki Ph.D. On August 14, 2024, the U.S. Food and Drug Administration (FDA) approved a colony stimulating factor-1 receptor (CSF-1R)-blocking antibody, NIKTIMVO ...
A retrospective cohort study design was used to analyze commercial claims data in adults with lung cancer initiated on chemotherapy from April 1, 2013, to March 30, 2015. The tool was implemented at ...
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...
The effects of sargramostim and filgrastim on hematopoietic cells are described. Filgrastim is a lineage-specific colonystimulating factor (CSF), mainly affecting neutrophils. In addition to enhancing ...
a FDA = Food and Drug Administration, G-CSF = granulocyte colony-stimulating factor, GM-CSF = granulocyte-macrophage colony-stimulating factor, CHO = Chinese hamster ovary, NA = not available.
A new study that including participants from the Central Institute of Mental Health in Mannheim shows how the growth factor erythropoietin (EPO) protects and regenerates nerve cells in the brain. In ...
The first-in-human clinical phase I trial assessing the feasibility and safety of WDVAX, an immunostimulatory biomaterial-based cancer vaccine, in a cohort of 21 patients with stage 4 metastatic ...
Autoimmune pulmonary alveolar proteinosis (aPAP) is a rare disease characterized by progressive surfactant accumulation and hypoxemia caused by autoantibodies against granulocyte–macrophage ...
Colony-stimulating factor 1 receptor (CSF1R)–dependent monocytes and macrophages are key mediators of chronic graft-versus-host disease (GVHD), a major long-term complication of allogeneic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results